-
Dr. Reddy's completes acquisition of U.S. penicillin facility, products from GSK
HYDERABAD, India — Dr. Reddy’s Labs will assume ownership of a penicillin manufacturing site in Bristol, Tenn., from GlaxoSmithKline.
The generic drug maker said it completed the acquisition of the facility and related product portfolio, including Augmentin and Amoxil brands. GSK will retain the existing rights for the aforementioned brands outside the United States.
Further financial terms and conditions of the transaction are not being disclosed.
-
Biodel elects new board chairman
DANBURY, Conn. — A biopharmaceutical company that specializes in diabetes treatments has appointed a new board chairman.
Biodel said that effective immediately, Brian Pereira, who has served on the drug maker's board since 2007, will become chairman. Current chairman Charles Sanders, who served as chairman since March 2010 after joining the board in August 2006, will continue to serve as a board member, Biodel said.